Navigation Links
AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
Date:11/30/2007

WILMINGTON, Del., Nov. 30 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) announced today that it has completed enrollment of patients in the ZEST (ZACTIMA Efficacy Study versus Tarceva) study, the first of four Phase III trials for the investigational once-daily oral anti-cancer drug vandetanib. Data from the study is expected in 2008.

ZEST is a randomized, double-blind, multi-center Phase III study to assess the efficacy of vandetanib versus erlotinib in overall survival (OS) and progression-free survival (PFS) in over 1,150 patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) after failure of first-line anti-cancer therapy.

"Non-small cell lung cancer is an area of high unmet medical need, and we hope vandetanib will offer a beneficial new treatment option for people with lung cancer," said Dr. Peter Langmuir, Medical Science Director at AstraZeneca.

ZEST is part of a Phase III clinical trial program to gain a broad understanding of how vandetanib may benefit people with lung cancer.

The other studies are:

-- ZODIAC (vandetanib + docetaxel versus docetaxel alone)

-- ZEAL (vandetanib + pemetrexed versus placebo + pemetrexed); and,

-- ZEPHYR (vandetanib + best supportive care (BSC) versus placebo + BSC).

These studies are currently recruiting patients.

The Phase III program in NSCLC follows results from two Phase II trials where vandetanib was studied either alone or in combination with standard chemotherapy (docetaxel). (1)(2) Vandetanib is also being evaluated as a treatment option in medullary thyroid cancer and has been awarded Food and Drug Administration (FDA) orphan drug status and fast track designation for this indication.

About AstraZeneca

AstraZeneca is a major international health care business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of health care services. It is one o
'/>"/>

SOURCE AstraZeneca
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
2. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
8. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
9. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
10. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
11. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... VIEJO, Calif. , Dec. 22, 2014 ... into expanded corporate offices in Aliso Viejo ... announced that due to the tremendous growth and worldwide ... needed. Sales of patented SnoreRx, the anti snore cure ... offices. He said, "We are now in 23 ...
(Date:12/22/2014)... a privately-held medical products and technologies company, today announced ... Officer of the company, effective December 22, 2014. ... Board of Directors of ConvaTec thanks Mr. Berger for ... years," said Magnus Lundberg , the Chairman of ... company is well positioned for the future."  The company ...
(Date:12/22/2014)... 2014  Mark Farrah Associates (MFA), www.markfarrah.com ... of the 2015 marketplace exchange projections and insights ... According to a recent ASPE (Office of ... of Health and Human Services) report, an estimated ... plans through the Marketplace as of October 2014 ...
Breaking Medicine Technology:ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2Insights into the Marketplace and Individual Market Growth 2
... importance of dedicated information management systems for radiation ... most recent version of its MOSAIQ® Oncology Information ... Systems Society,s 2012 conference (HIMSS12), Feb. 20-24, in ... comprehensive OIS that centralizes traditional radiation oncology, particle ...
... Feb. 16, 2012  Cardium Therapeutics (NYSE Amex: ... previously announced sale of 17,857,143 shares of its common ... of approximately $5.0 million, before deducting placement agent,s fees ... investors participating in the offering purchased the shares at ...
Cached Medicine Technology:Elekta Highlights Latest Version of MOSAIQ Oncology Information System at HIMSS12 Meeting 2Cardium Announces Closing of $5.0 Million Equity Financing 2Cardium Announces Closing of $5.0 Million Equity Financing 3
(Date:12/22/2014)... Super Saturday, the last Saturday before Christmas, is ... day in the 2014 holiday shopping season. , ... steady pre-Christmas stream of customers, ready to purchase marijuana ... definitely intend to take advantage…of the recreational cannabis as ... enjoying The Grass Station’s holiday sale on vape products. ...
(Date:12/22/2014)... Give a loved one the greatest gift of ... vitality. , For a limited time, HealthiPlus ( https://healthiplus.com/christmas-gift-packages/ ... special Holiday Wellness gift packages at drastically reduced prices ... contains cutting-edge, proven nutritional support for joints, mental functioning ... we age. , Joint Health Plus contains ...
(Date:12/22/2014)... Pasadena sleep apnea dentist, Dr. ... Drowsy drivers are 15 times more likely to cause ... some experts believe that sleep-deprived drivers may be just ... millions of Americans may be sleep-deprived without even knowing ... about 18 million Americans have sleep apnea, but as ...
(Date:12/22/2014)... 2014 TheHardwareCity.com now stocks MagnoGrip Pro ... useful features. Customers of the large online tool shop ... gloves delivered to their home or workplace with free ... that incorporate heavy duty magnets, which make work easier. ... to store metal parts on the back of their ...
(Date:12/22/2014)... 22, 2014 NAPW honors ... Woman of the Year. Ms. Foley is recognized with ... largest, most-recognized networking organization of professional women in the ... Association of Professional Women is a powerfully vibrant networking ... Chapters. , “As a nurse, I felt like I ...
Breaking Medicine News(10 mins):Health News:Customers at Colorado’s Grass Station Say They’re Enjoying the Experience of Legally Purchasing Marijuana this Year to Give as Christmas Presents to Friends and Family 2Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2Health News:MagnoGrip Pro Utility Magnetic Gloves on Sale at TheHardwareCity.com 2Health News:National Association of Professional Women Announces Michelle M. Foley, Vice President of Operations of OTTR Chronic Care Solutions, a 2014 Professional Woman of the Year 2
... ... Americans affected by infertility, RESOLVE: The National Infertility Association and Fertility LifeLines™, a free ... Film Competition. , ... (PRWEB) July 6, 2009 -- Lights, camera, action! To provide support and hope to ...
... (NYSE: CSC ) today announced that it will kick ... with the American Red Cross at CSC,s new global headquarters in ... marks the first in a series of blood drives toward meeting ... Chairman, President and Chief Executive Officer Michael W. Laphen; James W. ...
... 6 MasterCard Worldwide today announced a multi-year contract ... Bank to issue MasterCard cards for health savings accounts ... (HRAs), including the accounts they manage for UnitedHealthcare members. ... of payment, tied to these tax-advantaged accounts, for eligible ...
... (Amex: NBS ), which is pioneering the ... cells for future medical need, announced today it has ... the Company,s Vice President of Drug Development and Regulatory ... position will be overseeing NeoStem,s therapeutic development activities and ...
... July 6 Coapt Systems, Inc. ( www.coaptsystems.com ... FDA-approved hyaluronic acid based dermal filler for the treatment ... "smile lines." Hydrelle is the first FDA-approved hyaluronic ... patient comfort. Proven safe and effective, Hydrelle is ...
... ... dentistry,s responsibility in the recognition and management of snoring and sleep apnea, announces the launch ... ... LLC, the web,s fastest growing source of information on dentistry,s responsibility in the recognition and ...
Cached Medicine News:Health News:Calling All Aspiring Filmmakers! The In The Know Short Film Competition Announces Call for Entries Women and Couples Encouraged to Enter TODAY, Share Their Fertility Stories and Inspire Others 2Health News:Calling All Aspiring Filmmakers! The In The Know Short Film Competition Announces Call for Entries Women and Couples Encouraged to Enter TODAY, Share Their Fertility Stories and Inspire Others 3Health News:CSC to Kick Off National Blood Drive Campaign July 8 at Global Headquarters in Virginia 2Health News:MasterCard Extends Agreement With OptumHealth 2Health News:MasterCard Extends Agreement With OptumHealth 3Health News:NeoStem, Inc. Appoints International Expert in Endocrinology and Pharmacology as Vice President of Drug Development and Regulatory Affairs 2Health News:NeoStem, Inc. Appoints International Expert in Endocrinology and Pharmacology as Vice President of Drug Development and Regulatory Affairs 3Health News:NeoStem, Inc. Appoints International Expert in Endocrinology and Pharmacology as Vice President of Drug Development and Regulatory Affairs 4Health News:Coapt Systems, Inc. Launches Hydrelle(TM) a New, FDA-Approved Dermal Filler with Lidocaine for Significant Wrinkle Correction and Greater Patient Comfort 2Health News:Coapt Systems, Inc. Launches Hydrelle(TM) a New, FDA-Approved Dermal Filler with Lidocaine for Significant Wrinkle Correction and Greater Patient Comfort 3Health News:Coapt Systems, Inc. Launches Hydrelle(TM) a New, FDA-Approved Dermal Filler with Lidocaine for Significant Wrinkle Correction and Greater Patient Comfort 4Health News:Snoring Isn't Sexy, LLC Launches Discussion Forum for the Public 2
Research Series 2100 Adjustable-volume Pipette,100-1,000 l, single-channel with adjustable-volume setting...
... first Sysmex hematology analyzer designed for a ... its small footprint, closed tube sampling, and ... of whole blood sample, you have a ... the emergency room, surgical suite, or small ...
... The Integrity family of pacemakers ... and truly automatic devices in today's ... combination of automated features and diagnostic ... popular and proven Affinity pacemakers platform. ...
... PT System is an in vitro diagnostic ... results, expressed in seconds and INR units. ... It is intended for use by health ... to monitor patients who are on warfarin-type ...
Medicine Products: